| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7dba5aa1d0a9d744f2a07184ae4594d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4891
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate |
2021-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef90414e6ab8840a6265cdd19553bbdd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59361a525b75c9309e0d782be1364fb3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e537f3566ec58a0af8b6d824b4483aba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_520ffe85125a291dd719f4cf23833c6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5be3147d7ed95698198bbc9461ce796e |
| publicationDate |
2021-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021220317-A1 |
| titleOfInvention |
Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| abstract |
Described herein are pharmaceutical compositions comprising one or more fumarate esters and methods for treating multiple sclerosis subjects with the compositions where the incidence of gastrointestinal side effects is reduced compared to treatments comprising dimethyl fumarate (e.g., TECFIDERA®). In particular, described herein are oral pharmaceutical compositions comprising monomethyl fumarate in a liquid vehicle that have reduced gastrointestinal side effects. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11590095-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021161852-A1 |
| priorityDate |
2020-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |